EP3621643A4 - Anti-malarial antibodies that bind circumsporozoite protein - Google Patents
Anti-malarial antibodies that bind circumsporozoite protein Download PDFInfo
- Publication number
- EP3621643A4 EP3621643A4 EP18798204.6A EP18798204A EP3621643A4 EP 3621643 A4 EP3621643 A4 EP 3621643A4 EP 18798204 A EP18798204 A EP 18798204A EP 3621643 A4 EP3621643 A4 EP 3621643A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bind
- circumsporozoite protein
- malarial antibodies
- malarial
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710117490 Circumsporozoite protein Proteins 0.000 title 1
- 230000000078 anti-malarial effect Effects 0.000 title 1
- 239000003430 antimalarial agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762504863P | 2017-05-11 | 2017-05-11 | |
US201762560971P | 2017-09-20 | 2017-09-20 | |
US201762564066P | 2017-09-27 | 2017-09-27 | |
PCT/US2018/032366 WO2018209265A1 (en) | 2017-05-11 | 2018-05-11 | Anti-malarial antibodies that bind circumsporozoite protein |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3621643A1 EP3621643A1 (en) | 2020-03-18 |
EP3621643A4 true EP3621643A4 (en) | 2021-07-21 |
Family
ID=64105059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18798204.6A Pending EP3621643A4 (en) | 2017-05-11 | 2018-05-11 | Anti-malarial antibodies that bind circumsporozoite protein |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3621643A4 (en) |
WO (1) | WO2018209265A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
US20220064327A1 (en) | 2018-12-21 | 2022-03-03 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
WO2020227228A2 (en) * | 2019-05-03 | 2020-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
WO2021001351A1 (en) * | 2019-07-01 | 2021-01-07 | Deutsches Krebsforschungszentrum | Plasmodium antibodies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028644A1 (en) * | 2012-08-15 | 2014-02-20 | Cyvax, Inc. | Methods and compositions for preventing a condition |
WO2017163049A1 (en) * | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0513421D0 (en) * | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
WO2015075070A1 (en) * | 2013-11-20 | 2015-05-28 | Cmc Biologics A/S | A bioreactor system and method for producing a biopolymer |
-
2018
- 2018-05-11 EP EP18798204.6A patent/EP3621643A4/en active Pending
- 2018-05-11 WO PCT/US2018/032366 patent/WO2018209265A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028644A1 (en) * | 2012-08-15 | 2014-02-20 | Cyvax, Inc. | Methods and compositions for preventing a condition |
WO2017163049A1 (en) * | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
Non-Patent Citations (3)
Title |
---|
CRAIG PRZYSIECKI ET AL: "Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex", FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, vol. 2, 1 January 2012 (2012-01-01), pages 1 - 11, XP055375838, DOI: 10.3389/fcimb.2012.00146 * |
ROBERTO ANKER ET AL: "VH and VL region structure of antibodies that recognize the (NANP)s dodecapeptide sequence in the circumsporozoite protein of Plasmodium falciparum", EUR. J. IMMUNOL, vol. 20, 1 January 1990 (1990-01-01), pages 2757 - 2761, XP055374618, DOI: 10.1002/eji.1830201233 * |
See also references of WO2018209265A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3621643A1 (en) | 2020-03-18 |
WO2018209265A1 (en) | 2018-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3589313A4 (en) | Anti-tigit antibodies | |
EP3481869A4 (en) | Anti-cd73 antibodies | |
EP3498840A4 (en) | Anti-lag-3 antibody | |
IL260846B (en) | Antigen binding proteins that bind pd-l1 | |
EP3325009A4 (en) | Antibody therapeutics that bind lag3 | |
EP3334757A4 (en) | Anti-tigit antibodies | |
EP3256165A4 (en) | Antibody therapeutics that bind ctla4 | |
EP3297671A4 (en) | Anti-ror1 antibodies | |
EP3265125A4 (en) | Antibody therapeutics that bind cd47 | |
EP3354729A4 (en) | Anti-garp antibody | |
EP3621643A4 (en) | Anti-malarial antibodies that bind circumsporozoite protein | |
EP3661558A4 (en) | Anti-il1rap antibodies | |
EP3492591A4 (en) | Anti-b7-h4 antibody | |
EP3606961B8 (en) | Garp-tgf-beta antibodies | |
EP3252074A4 (en) | Anti-alk2 antibody | |
EP3183001A4 (en) | Antigen binding proteins that bind cxcr5 | |
EP3581587A4 (en) | Anti-coagulation factor xi antibody | |
EP3691447A4 (en) | Anti-transthyretin antibodies | |
EP3349794A4 (en) | Anti-cd115 antibodies | |
EP3563868A4 (en) | Pharmaceutical preparation stably comprising cd147 monoclonal antibody | |
EP3297662A4 (en) | Antibodies that bind to axl proteins | |
EP3526247A4 (en) | Anti-il1-rap antibodies | |
EP3381941A4 (en) | Anti-epha4 antibody | |
EP3266872A4 (en) | Novel anti-pad4 antibody | |
EP3526251A4 (en) | Anti-p53 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191211 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WATSON, SIMON JAMES Inventor name: LIANG, QI Inventor name: EMERLING, DANIEL ERIC Inventor name: CARROLL, SEAN MATTHEW Inventor name: KELLAM, PAUL Inventor name: BRADLEY, ALLAN Inventor name: BINTER, PELA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KYMAB LIMITED Owner name: ATRECA, INC. |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210618 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/015 20060101AFI20210614BHEP Ipc: C07K 14/445 20060101ALI20210614BHEP Ipc: C12N 15/09 20060101ALI20210614BHEP Ipc: C12N 1/21 20060101ALI20210614BHEP Ipc: C07K 16/20 20060101ALI20210614BHEP |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KYMAB LIMITED Owner name: ATRECA, INC. |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230807 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240508 |